Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pravastatin Reduces Risk of Stroke: Prof. Sacks of Harvard
February 11, 2002
- Amrubicin, Gatifloxacin Recommended for Approval
February 11, 2002
- Efficient Drug Development Expected with Human Tissue Bank: JHSF
February 11, 2002
- Korosho Considers Issuing Its Own List of Essential Drugs
February 11, 2002
- WORLD NEWS IN BRIEF
February 11, 2002
- Number of Births Continues to Decrease
February 11, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 11, 2002
- Pharmacoeconomic Data Not Reflected in NHI Pricing: Expert
February 11, 2002
- Kyu-Yu-Kai, Efco to Merge in April
February 11, 2002
- Survey Shows Marked Decreases in People's Interest in Science
February 11, 2002
- P&G to Sell Vicks Medicated Drop Business
February 11, 2002
- REGULATORY NEWS IN BRIEF
February 11, 2002
- Olympus Develops DNA Computer for Gene Analysis
February 11, 2002
- Yamanouchi, Sumitomo Chemical Tie Up on Knockout Mice with Transgenic Inc
February 11, 2002
- Eiken Develops New Bovine Embryo Sexing Reagent
February 11, 2002
- Tanabe Ties Up with Menarini to Develop Antitumor Agent
February 11, 2002
- BML to Merge 2 Subsidiaries
February 11, 2002
- Sanuki, Ohmori Yakuhin Shikoku, Baikado to Form Koyo on April 1
February 4, 2002
- Daiwa, Kowa to Tie Up in Shikoku
February 4, 2002
- Medical Fee Reduction to Seriously Hit Medical Institutions: JMARI
February 4, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…